人民财讯12月5日电，12月5日，信达生物公告，完成与武田制药的全球战略合作相关协议。根据协议约 定，信达生物已向武田制药配发及发行约691.38万股股份，占公司扩大后总股本的0.4%；此次股份认购 价为每股112.56港元，较公司前一交易日收盘价溢价20.3%，且该部分股份设有一年禁售期。本次交易 合计涉资约7.78亿港元，扣除相关费用后，实际募资净额约7.77亿港元。 ...

智通财经APP讯，信达生物(01801)发布公告，内容有关信达生物与武田制药(透过武田制药全资附属公 司Takeda Pharmaceuticals International AG)达成全球战略合作，许可、选择权及合作协议及股份发行协 议各自的所有先决条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行 协议于2025年12月4日完成。 于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 ...

信达生物(01801)发布公告，内容有关信达生物与武田制药(透过武田制药全资附属公司Takeda Pharmaceuticals International AG)达成全球战略合作，许可、选择权及合作协议及股份发行协议各自的所 有先决条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行协议于2025 年12月4日完成。 于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 ...

于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本 的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元(按每股认购股份112.56港元的认购价 计算)，而所得款项净额约为7.77亿港元。 格隆汇12月5日丨信达生物(01801.HK)宣布，许可、选择权及合作协议及股份发行协议各自的所有先决 条件均已达成或获豁免(如适用)。因此，许可、选择权及合作协议已完成及股份发行协议于2025年12月 4日完成。 ...

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01801 | 說明 | 普通股每股面值0.00001美元 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） （股份代號：1801） 完成與武田製藥的全球戰略合作及根據一般授權發行股份 董事會欣然宣佈，許可、選擇權及合作協議及股份發行協議各自之所有先決條件 均已達成或獲豁免（如適用）。因此，許可、選擇權及合作協議已完成及股份發行 協議於2025年12月4日完成。 於股份發行協議完成後，本公司向認購人配發及發行6,913,834股股份，佔發行認 購股份後本公司已發行股本之約0.40%。配發及發行認購股份之所得款項總額約 為778百萬港元（按每股認購股份112.56港元之認購價計算），而所得款項淨額（經 扣除配發及發行認購股份之所有相關開支後）約為777百萬港元。有關所得款項用 途之進一步詳情，請參閱該公告。 認購股份乃根據一般授權發行。一般授權 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01801 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,713,783,235 | | 0 | | 1,713,783,235 | | 增加 / 減少 (-) | | | 80,001 | | 0 | | | | 本月底結存 | | | 1,713,863,236 | | 0 | | 1,713,863,236 | 公司名稱: 信達生物製藥 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | ...

Core Insights - The article reports that Innovent Biologics has received approval for its first domestically developed IL-23 p19 targeted drug, Pikanqi Baiduan (匹康奇拜单抗), for the treatment of moderate to severe plaque psoriasis, marking a significant milestone in the Chinese pharmaceutical industry [1][3]. Drug Approval and Development - Pikanqi Baiduan is a recombinant anti-IL-23p19 antibody that specifically binds to the IL-23p19 subunit, blocking the IL-23 receptor-mediated signaling pathway to exert anti-inflammatory effects [1][3]. - The approval is based on the positive results from the Phase III CLEAR-1 clinical trial, which met all primary and key secondary endpoints [3]. Company Portfolio - As of now, Innovent Biologics has a total of 16 new drugs approved for market, including 12 innovative drugs and 2 improved biological products, with a focus on oncology, metabolism, and autoimmune diseases [6].

Core Insights - The approval of Xinmei Yue (Pikangqibai Injection) by the National Medical Products Administration (NMPA) marks a significant advancement in the treatment of moderate to severe plaque psoriasis in adults, being the first domestically developed IL-23p19 monoclonal antibody in China [1][2] - Psoriasis is a chronic, relapsing inflammatory disease affecting over 7 million patients in China, with a significant portion suffering from moderate to severe forms, highlighting the need for effective and personalized treatment options [1] - The CLEAR-1 study demonstrated that Xinmei Yue achieved a PASI90 response rate of 80.3% at week 16, making it the first IL-23p19 antibody to surpass this threshold in a registered phase III clinical trial [2] Company Developments - Xinmei Yue is the 17th product launched by Innovent Biologics and is a key product in the company's autoimmune portfolio, which is becoming a vital growth driver for the company [2] - The innovative engineering of the antibody structure allows Xinmei Yue to have the longest maintenance dosing interval among similar biologics, requiring only four doses per year, which enhances patient convenience [2] - The company plans to further research Xinmei Yue for additional psoriasis subtypes, psoriatic arthritis, and pediatric psoriasis to expand its therapeutic value and meet clinical needs [2]

Core Viewpoint - Innovent Biologics (1801.HK) has received approval from the National Medical Products Administration (NMPA) for its monoclonal antibody injection, Pikanqibai (brand name: Xinmeiyue), for the treatment of moderate to severe plaque psoriasis in adult patients, marking it as the first domestically developed IL-23p19 targeted monoclonal antibody in China [1] Company Summary - The newly approved drug is based on the Phase III CLEAR-1 study conducted in China, demonstrating that over 80% of patients achieved a clearance of more than 90% of skin lesions after four months of treatment [1] - Pikanqibai offers a maintenance treatment regimen with a dosing frequency of once every 12 weeks, which is the longest maintenance dosing interval among similar biologics, requiring only four doses per year [1] - The company plans to continue research on Pikanqibai for other psoriasis subtypes, psoriatic arthritis, and pediatric psoriasis [1] Industry Summary - Psoriasis is a chronic, relapsing, inflammatory, and systemic disease influenced by the interaction between individual and environmental factors, characterized by recurrent episodes and lifelong management [1] - It is estimated that there are over 7 million psoriasis patients in China, with plaque psoriasis being the most common type, and approximately 30% of these patients classified as moderate to severe [1]